Acute Cholecystitis: Diagnosis, Severity Grading, and When to Operate

L'essentiel

Initial workup

• Diagnosis rests on right upper quadrant pain or a Murphy sign, systemic inflammation (fever, leukocytosis), and confirmatory ultrasound — no further imaging is needed in a typical case. Reserve CT or MRI/MRCP for diagnostic uncertainty, suspected gangrenous or emphysematous cholecystitis or perforation, or rising bilirubin and alkaline phosphatase suggesting common bile duct stones.
• Assign Tokyo severity: Grade III = any organ dysfunction (vasopressor need, altered mentation, PaO2/FiO2 < 300, creatinine > 2, INR > 1.5, platelets < 100,000); Grade II = WBC > 18,000, a palpable tender RUQ mass, symptoms > 72 hours, or marked local inflammation (gangrenous or emphysematous change, pericholecystic abscess); Grade I = neither.
• Labs and workup to guide surgery: CBC, CMP with liver tests, lipase, coagulation studies, blood cultures if febrile or rigoring, EKG, and a surgical risk assessment (comorbidities, frailty, anticoagulant or antiplatelet use). Normal bilirubin and alkaline phosphatase make concurrent choledocholithiasis unlikely but do not exclude it.

Acute management

• Surgical consultation on admission — the key decision is timing, not whether to operate. NPO, IV crystalloid, scheduled analgesia (an NSAID such as ketorolac if renal function permits, plus opioid as needed), and antiemetics.
• Empiric antibiotics targeting enteric gram-negatives and streptococci: ceftriaxone 1–2 g IV every 24 hours (or cefazolin 2 g IV every 8 hours) for community-acquired Grade I–II disease; add metronidazole 500 mg IV every 8 hours for a biliary-enteric anastomosis, suspected anaerobic or gangrenous disease, or Grade III.
• For beta-lactam allergy or healthcare-associated or recent antibiotic exposure, piperacillin-tazobactam 3.375 g IV every 6 hours (extended infusion preferred) or a carbapenem; add enterococcal or MRSA coverage only in severe, healthcare-associated, immunosuppressed, or post-instrumentation cases.
• Plan laparoscopic cholecystectomy during this admission, ideally within about 72 hours. Early surgery shortens length of stay by roughly 3–4 days without increasing bile duct injury, conversion, or postoperative complications, and nationwide data favor operating on hospital days 1–3 over day 0 or day 5 and later.
• Do not delay surgery to cool off with antibiotics simply because symptoms began more than 72 hours ago — early cholecystectomy during the index admission remains safe and reduces composite morbidity in that group.

Inpatient and longitudinal management

• When cholecystectomy achieves adequate source control in Grade I–II disease, stop antibiotics within about 24 hours postoperatively; prolonged courses add no benefit. Without source control (nonoperative management or cholecystostomy alone), treat about 4–7 days from drainage and transition to oral therapy (amoxicillin-clavulanate, or a fluoroquinolone with or without metronidazole, culture-directed) once afebrile and tolerating oral intake.
• If managed nonoperatively, counsel that recurrent biliary events are common and arrange interval cholecystectomy, typically at about 6 weeks, once the patient is a suitable operative candidate.
• If bilirubin or alkaline phosphatase rise, the common bile duct is dilated, or cholangitis develops, obtain MRCP or proceed to ERCP for stone clearance before or after cholecystectomy; intraoperative cholangiography is an alternative when suspicion is intermediate.
• Routine inpatient care: VTE prophylaxis, early mobilization, a perioperative hold-and-resume plan for anticoagulants, and glycemic control.

Monitoring and disposition

• A medicine floor is appropriate for Grade I disease: vitals every 4–6 hours, daily WBC and liver tests, and daily reassessment of the abdominal exam and pain control.
• Expect defervescence and a falling WBC within 24–48 hours of effective therapy; lack of improvement should trigger re-imaging and surgical re-evaluation.
• After cholecystectomy, watch for bile leak (persistent pain, fever, ileus, rising bilirubin) and surgical site infection; advance diet as tolerated. Most Grade I patients discharge within 1–2 days postoperatively.
• Discharge criteria: afebrile, pain controlled on oral analgesia, tolerating a diet, stable or improving labs, and a defined antibiotic stop date. Surgical follow-up in 2–4 weeks; if discharged without cholecystectomy, confirm a scheduled interval operation and give return precautions for fever, jaundice, or recurrent pain.
• If a cholecystostomy tube is in place at discharge, arrange tube care instructions, output monitoring, and interventional radiology or surgical follow-up for cholangiogram and tube removal.

Escalate care if

• Hypotension, a vasopressor requirement, altered mentation, or new renal, hepatic, or coagulation dysfunction — Tokyo Grade III: ICU transfer, broaden to piperacillin-tazobactam or a carbapenem, and arrange urgent source control (emergency drainage or cholecystectomy depending on operative risk).
• The patient is a high-risk surgical candidate (severe cardiopulmonary disease, frailty, Grade III physiology not improving, or prohibitive anesthetic risk) — percutaneous cholecystostomy for source control, with interval cholecystectomy considered after recovery.
• Fever, pain, or leukocytosis fail to improve after about 48 hours of antibiotics without definitive source control — re-image for gangrenous or emphysematous cholecystitis, perforation, or pericholecystic abscess and escalate to urgent drainage or cholecystectomy; delay in source control is associated with increased mortality.
• Jaundice, rigors, and RUQ pain (Charcot triad) emerge — treat as acute cholangitis with urgent biliary decompression by ERCP.
• Acalculous cholecystitis is identified (no stones; typically critically ill, postoperative, prolonged fasting or TPN, or severe comorbidity) — antibiotics plus percutaneous cholecystostomy as the preferred initial source control since these patients are usually poor operative candidates; cholecystectomy is reserved for gangrene or perforation or for fit patients, and the catheter is removed after a cholangiogram confirms cystic duct patency and clinical resolution.

Duration

Antibiotics run preoperatively plus no more than 24 hours after cholecystectomy when source control is adequate in Grade I–II disease, or approximately 4–7 days from drainage when definitive source control is not achieved, with an early IV-to-oral switch once improving.

Mises en garde

• The pathway above assumes Grade I disease; a palpable tender RUQ mass, symptom duration over 72 hours, WBC over 18,000, or marked local inflammation reclassifies to Grade II and favors more urgent surgical or drainage source control.
• Avoid NSAIDs with renal impairment, active GI bleeding, or significant heart failure; dose-adjust antibiotics for renal function.
• Percutaneous cholecystostomy is relative-risk-dependent: correct coagulopathy and hold therapeutic anticoagulation when feasible before drain placement.
• Early cholecystectomy carries a modest increase in minor intraoperative events without an increase in bile duct injury or postoperative complications.

Références

1. WSES/GAIS/SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infections. World Journal of Emergency Surgery. (2021) · Recommandation officielle“Studies of septic patients undergoing source control for IAIs suggest that delays of only 3–6 h were associated with an increased mortality.”
2. Early Versus Delayed Laparoscopic Cholecystectomy for Acute Calculous Cholecystitis: A Systematic Review. (2026) · Revue systématique“Initial management includes analgesia, intravenous fluid resuscitation, and antibiotics, followed by definitive treatment with surgery.”
3. The optimal timing of laparoscopic cholecystectomy for acute cholecystitis according to symptom onset and patient admission: a meta-analysis of randomised controlled trials. (2026) · Revue systématique“Early laparoscopic cholecystectomy reduces hospital stay without increasing major morbidity or bile duct injury.”
4. Acute Cholecystitis — Optimal Timing for Early Cholecystectomy: a French Nationwide Study. Journal of Gastrointestinal Surgery. · Source primaire“For patients with acute calculous cholecystitis, all efforts should be made to perform cholecystectomy within 3 days after hospital admission in order to decrease morbidity and mortality.”